Literature DB >> 32618346

Vascular Endothelial Growth Factor Receptor-3 Expression Predicts Sentinel Node Status in Primary Cutaneous Melanoma.

Ferdinand Toberer1, Holger A Haenssle, Martin Laimer, Monika Heinzel-Gutenbrunner, Alexander Enk, Wolfgang Hartschuh, Peter Helmbold, Heinz Kutzner.   

Abstract

This study analysed the expression of vascular endothelial growth factor-A (VEGF), VEGFR-2, and VEGFR-3 in primary cutaneous melanomas with positive and negative sentinel node status (SLN) (a total of 58 specimens divided into 2 groups of 29 for each status). The specimens were collected from the pathological archive of the department of Dermatology, Venereology and Allergology of the University Medical Center Heidelberg. A quantification score was developed for protein expression, by considering the percentage of positive melanoma cells (0: 0%, 1: up to 1%, 2: 2-10%, 3: 11-50%, and 4: > 50%) in relation to the intensity of staining (0: negative, 1: low, 2: medium, 3: strong). Tumoural VEGFR-3 expression (mean ± standard deviation) in SLN+ tumours (9.62 ± 3.09) was significantly stronger than in SLN- tumours (6.13 ± 3.87; p < 0.001). A binary logistic regression model proved VEGFR-3 expression and tumour thickness to be significant independent predictors of SLN. These data provide evidence that VEGFR-3 expression may play a critical role in the pathogenesis of malignant melanoma and that its investigation may help to improve the selection of patients with primary cutaneous melanoma for sentinel node biopsy.

Entities:  

Keywords:  VEGF; VEGFR-2; VEGFR-3; angiogenesis; sentinel node biopsy; melanoma

Mesh:

Substances:

Year:  2020        PMID: 32618346      PMCID: PMC9207649          DOI: 10.2340/00015555-3588

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  31 in total

1.  Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.

Authors:  Markku Miettinen; Maarit-Sarlomo Rikala; Janusz Rys; Jerzy Lasota; Zeng-Feng Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.

Authors:  Marion Wobser; Claudia Siedel; David Schrama; Eva-B Bröcker; Juergen C Becker; Claudia S Vetter-Kauczok
Journal:  Arch Dermatol Res       Date:  2006-01-03       Impact factor: 3.017

3.  Probability of sentinel lymph node positivity in melanoma.

Authors:  Mary-Ann El Sharouni; Arjen J Witkamp; Vigfús Sigurdsson; Paul J van Diest
Journal:  Eur J Cancer       Date:  2019-06-01       Impact factor: 9.162

4.  Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.

Authors:  Oriana Simonetti; Guendalina Lucarini; Donatella Brancorsini; Petronela Nita; Maria Luisa Bernardini; Graziella Biagini; Annamaria Offidani
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

5.  Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.

Authors:  H Peach; R Board; M Cook; P Corrie; S Ellis; J Geh; P King; G Laitung; J Larkin; J Marsden; M Middleton; M Moncrieff; P Nathan; B Powell; R Pritchard-Jones; S Rodwell; N Steven; P Lorigan
Journal:  J Plast Reconstr Aesthet Surg       Date:  2019-06-28       Impact factor: 2.740

6.  Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.

Authors:  Sandra L Wong; Mark B Faries; Erin B Kennedy; Sanjiv S Agarwala; Timothy J Akhurst; Charlotte Ariyan; Charles M Balch; Barry S Berman; Alistair Cochran; Keith A Delman; Mark Gorman; John M Kirkwood; Marc D Moncrieff; Jonathan S Zager; Gary H Lyman
Journal:  Ann Surg Oncol       Date:  2017-12-13       Impact factor: 5.344

7.  Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience.

Authors:  N Cascinelli; F Belli; M Santinami; V Fait; A Testori; W Ruka; R Cavaliere; N Mozzillo; C R Rossi; R M MacKie; O Nieweg; M Pace; K Kirov
Journal:  Ann Surg Oncol       Date:  2000-07       Impact factor: 5.344

8.  Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

Authors:  Neil R Smith; Dawn Baker; Neil H James; Kirsty Ratcliffe; Martin Jenkins; Susan E Ashton; Graham Sproat; Ruth Swann; Neil Gray; Anderson Ryan; Juliane M Jürgensmeier; Chris Womack
Journal:  Clin Cancer Res       Date:  2010-07-06       Impact factor: 12.531

9.  Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma.

Authors:  James S Goydos; David H Gorski
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

10.  Immunologic escape and angiogenesis in human malignant melanoma.

Authors:  Pedro Redondo; Ignacio Sánchez-Carpintero; Ana Bauzá; Michel Idoate; Teresa Solano; Martin C Mihm
Journal:  J Am Acad Dermatol       Date:  2003-08       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.